- Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
- Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
- Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
- Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
- Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
- Fate Therapeutics to Present at Upcoming March Investor Conferences
- Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
More ▼
Key statistics
On Thursday, Fate Therapeutics Inc (FATE:NMQ) closed at 3.43, 110.43% above the 52 week low of 1.63 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.66 |
---|---|
High | 3.66 |
Low | 3.40 |
Bid | 2.77 |
Offer | 5.48 |
Previous close | 3.43 |
Average volume | 2.47m |
---|---|
Shares outstanding | 113.83m |
Free float | 112.03m |
P/E (TTM) | -- |
Market cap | 390.44m USD |
EPS (TTM) | -1.92 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼